Melvin Rabena

3.6k total citations · 3 hit papers
19 papers, 2.6k citations indexed

About

Melvin Rabena is a scholar working on Ophthalmology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Melvin Rabena has authored 19 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Ophthalmology, 11 papers in Radiology, Nuclear Medicine and Imaging and 2 papers in Immunology. Recurrent topics in Melvin Rabena's work include Retinal Diseases and Treatments (16 papers), Retinal and Optic Conditions (8 papers) and Retinal Imaging and Analysis (6 papers). Melvin Rabena is often cited by papers focused on Retinal Diseases and Treatments (16 papers), Retinal and Optic Conditions (8 papers) and Retinal Imaging and Analysis (6 papers). Melvin Rabena collaborates with scholars based in United States, Italy and Germany. Melvin Rabena's co-authors include Dante J. Pieramici, Robert L. Avery, Ma'an Nasir, Alessandro Castellarin, Matthew Giust, Arun Patel, Joel Pearlman, Robert Wendel, Robert F. See and Nathan Steinle and has published in prestigious journals such as Ophthalmology, Investigative Ophthalmology & Visual Science and British Journal of Ophthalmology.

In The Last Decade

Melvin Rabena

18 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

2006 953 citations Robert L. Avery, Dante J. Pieramici et al. Ophthalmology profile →
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy

2006 603 citations Robert L. Avery, Joel Pearlman et al. Ophthalmology profile →
Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

2014 284 citations Robert L. Avery, Alessandro Castellarin et al. British Journal of Ophthalmology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melvin Rabena United States	13	2.3k	1.8k	463	132	94	19	2.6k
Ma'an Nasir United States	16	2.4k 1.1×	1.9k 1.0×	448 1.0×	195 1.5×	94 1.0×	24	2.7k
Catherine Meyerle United States	24	2.9k 1.2×	1.8k 1.0×	523 1.1×	141 1.1×	32 0.3×	50	3.1k
Philipp S. Muether Germany	27	1.3k 0.6×	1.1k 0.6×	296 0.6×	101 0.8×	97 1.0×	55	1.7k
Anat Loewenstein Israel	25	2.0k 0.9×	1.6k 0.9×	321 0.7×	123 0.9×	31 0.3×	120	2.3k
Kevin J. Blinder United States	29	2.4k 1.0×	1.7k 1.0×	357 0.8×	366 2.8×	53 0.6×	91	2.6k
Giulio Barteselli United States	23	1.5k 0.7×	1.1k 0.6×	330 0.7×	145 1.1×	26 0.3×	69	1.8k
H. Michael Lambert United States	18	1.5k 0.7×	1.1k 0.6×	653 1.4×	139 1.1×	114 1.2×	36	1.9k
Taku Wakabayashi Japan	28	2.1k 0.9×	1.7k 1.0×	670 1.4×	278 2.1×	64 0.7×	111	2.9k
H. Logan Brooks United States	12	1.2k 0.5×	932 0.5×	251 0.5×	258 2.0×	52 0.6×	25	1.4k
Raffaele Parrozzani Italy	26	1.4k 0.6×	802 0.5×	273 0.6×	271 2.1×	125 1.3×	95	1.8k

Countries citing papers authored by Melvin Rabena

Since Specialization

Citations

This map shows the geographic impact of Melvin Rabena's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Rabena with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Rabena more than expected).

Fields of papers citing papers by Melvin Rabena

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Rabena. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Rabena. The network helps show where Melvin Rabena may publish in the future.

Co-authorship network of co-authors of Melvin Rabena

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Rabena. A scholar is included among the top collaborators of Melvin Rabena based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Rabena. Melvin Rabena is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Chang, Margaret, Derrick Kaufman, Melvin Rabena, et al.. (2022). Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology. 140(8). 771–771. 15 indexed citations

Dreyer, Richard F., et al.. (2019). Patient experience data from the phase 2 Ladder trial of the Port Delivery System with ranibizumab. Investigative Ophthalmology & Visual Science. 60(9). 5388–5388. 1 indexed citations

Holekamp, Nancy M., Charles C. Wykoff, Steffen Schmitz-Valckenberg, et al.. (2019). Natural History of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. 127(6). 769–783. 59 indexed citations

Avery, Robert L., Alessandro Castellarin, Nathan Steinle, et al.. (2017). SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB. Retina. 37(10). 1847–1858. 241 indexed citations

Kiss, Szilárd, Steven M. Butler, Sherri Van Everen, et al.. (2015). Association of Geographic Atrophy (GA) and Visual Acuity (VA) with anti-VEGF Therapy Exposure in the Comparison of Age-related Macular Degeneration Treatments Trial (CATT). 56(7). 2837–2837. 1 indexed citations

Dhoot, Dilsher S., Dante J. Pieramici, Ma'an Nasir, et al.. (2015). Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye. 29(4). 534–541. 34 indexed citations

Avery, Robert L., Alessandro Castellarin, Nathan Steinle, et al.. (2014). Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. British Journal of Ophthalmology. 98(12). 1636–1641. 284 indexed citations breakdown →

Quezada-Ruiz, Carlos, Dante J. Pieramici, Ma'an Nasir, Melvin Rabena, & Robert L. Avery. (2014). SEVERE ACUTE VISION LOSS, DYSCHROMATOPSIA, AND CHANGES IN THE ELLIPSOID ZONE ON SD-OCT ASSOCIATED WITH INTRAVITREAL OCRIPLASMIN INJECTION. Retinal Cases & Brief Reports. 9(2). 145–148. 20 indexed citations

Risard, Sarah, Dante J. Pieramici, Melvin Rabena, et al.. (2011). INTRAVITREAL RANIBIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina. 31(6). 1060–1067. 18 indexed citations

10.

Pieramici, Dante J., Sarah Risard, & Melvin Rabena. (2009). RETINAL NEOVASCULARIZATION ASSOCIATED WITH A RETINAL ARTERIAL MACROANEURYSM. Retinal Cases & Brief Reports. 3(4). 415–418. 2 indexed citations

11.

Risard, Sarah, Dante J. Pieramici, & Melvin Rabena. (2009). CYSTOID MACULAR EDEMA SECONDARY TO PACLITAXEL (ABRAXANE). Retinal Cases & Brief Reports. 3(4). 383–385. 15 indexed citations

12.

Pieramici, Dante J. & Melvin Rabena. (2008). Anti-VEGF therapy: comparison of current and future agents. Eye. 22(10). 1330–1336. 86 indexed citations

13.

Pieramici, Dante J., Robert L. Avery, Alessandro Castellarin, et al.. (2007). Ranibizumab for the Treatment of Macular Edema Associated With Perfused Central Retinal Vein Occlusions. Investigative Ophthalmology & Visual Science. 48(13). 313–313.

14.

Avery, Robert L., Dante J. Pieramici, Melvin Rabena, et al.. (2007). Intravitreal Bevacizumab (Avastin®) in the Surgical Treatment of Proliferative Diabetic Retinopathy. Investigative Ophthalmology & Visual Science. 48(13). 4031–4031. 1 indexed citations

15.

Rabena, Melvin, Dante J. Pieramici, Alessandro Castellarin, Ma'an Nasir, & Robert L. Avery. (2007). INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION. Retina. 27(4). 419–425. 207 indexed citations

16.

Pieramici, Dante J., Robert L. Avery, Alessandro Castellarin, Ma'an Nasir, & Melvin Rabena. (2006). CASE OF ANTERIOR UVEITIS AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB. Retina. 26(7). 841–842. 45 indexed citations

17.

Avery, Robert L., Dante J. Pieramici, Melvin Rabena, et al.. (2006). Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration. Ophthalmology. 113(3). 363–372.e5. 953 indexed citations breakdown →

18.

Avery, Robert L., Joel Pearlman, Dante J. Pieramici, et al.. (2006). Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy. Ophthalmology. 113(10). 1695–1705.e6. 603 indexed citations breakdown →

19.

Verardo, Mark R., et al.. (2005). Glial Hypertrophy and Neuronal Remodeling in Mice Deficient in GFAP and Vimentin Following Experimental Retinal Detachment. 46(13). 2443–2443. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact